Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Rating of "Buy" by Analysts

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have received a consensus recommendation of "Buy" from the nine analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $31.8586.

A number of research analysts recently weighed in on the company. Wedbush reaffirmed an "outperform" rating and set a $30.00 price objective on shares of Bicara Therapeutics in a report on Friday, May 23rd. Wells Fargo & Company raised Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 price objective on the stock in a report on Friday, May 23rd. HC Wainwright dropped their price objective on Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Finally, Wall Street Zen lowered Bicara Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd.

Institutional Investors Weigh In On Bicara Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Red Tree Management LLC acquired a new stake in shares of Bicara Therapeutics in the fourth quarter valued at about $55,230,000. Vestal Point Capital LP grew its stake in shares of Bicara Therapeutics by 290.0% in the first quarter. Vestal Point Capital LP now owns 2,768,975 shares of the company's stock valued at $36,080,000 after buying an additional 2,058,975 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its stake in shares of Bicara Therapeutics by 171.9% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company's stock valued at $37,893,000 after buying an additional 1,375,265 shares in the last quarter. Braidwell LP grew its stake in shares of Bicara Therapeutics by 8.1% in the first quarter. Braidwell LP now owns 2,162,803 shares of the company's stock valued at $28,181,000 after buying an additional 162,144 shares in the last quarter. Finally, Deep Track Capital LP grew its stake in shares of Bicara Therapeutics by 151.0% in the fourth quarter. Deep Track Capital LP now owns 2,000,000 shares of the company's stock valued at $34,840,000 after buying an additional 1,203,148 shares in the last quarter.

Bicara Therapeutics Stock Down 2.3%

BCAX opened at $10.20 on Friday. Bicara Therapeutics has a 52 week low of $7.80 and a 52 week high of $28.09. The business's 50 day moving average is $10.41 and its two-hundred day moving average is $11.99.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.28). Sell-side analysts forecast that Bicara Therapeutics will post -2.59 EPS for the current year.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.